FBRX - CIK 0001419041
The table below shows Forte Biosciences, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $76.96M | $22.24M | $37.13M | $41.10M | $42.04M | $58.77M |
| Short-term investments | $36.12M | $36.12M | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $80.59M |
| $61.35M |
| $38.33M |
| $41.51M |
| $42.52M |
| $59.90M |
| Property, plant & equipment | $129.00K | $77.00K | $109.00K | - | $97.00K | $97.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $82.78M | $61.56M | $38.98M | $42.00M | $43.31M | $61.24M |
| Accounts payable | $9.99M | $4.88M | $1.42M | $1.15M | $946.00K | $1.24M |
| Total current liabilities | $20.75M | $9.08M | $3.67M | $3.18M | $1.76M | $2.26M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $21.79M | - | - | - | - | - |
| Retained earnings | -$223.37M | -$154.00M | -$118.52M | -$87.04M | -$73.17M | -$51.46M |
| Total equity | $60.99M | $52.48M | $35.31M | $38.82M | $41.55M | $58.98M |